CRYSTALLINE FORMS OF ASPACYTARABINE

The present invention relates to novel crystalline polymorphs, Form C and Form D, of (S)-2-amino-4-((1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-4-oxobutanoic acid (also known as BST-236, Astarabine® or Aspacytarabine), processes of pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LIDOR-HADAS, Ramy, TESSLER, Shoshi, SHUMILOV, Margarita
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to novel crystalline polymorphs, Form C and Form D, of (S)-2-amino-4-((1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-4-oxobutanoic acid (also known as BST-236, Astarabine® or Aspacytarabine), processes of preparation thereof, and uses thereof for the treatment of neoplastic diseases. La présente invention concerne de nouveaux polymorphes cristallins, de forme C et de forme D, de l'acide (S)-2-amino-4-((1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxyméthyl)tétrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-4-oxobutanoïque (également connu sous le nom de BST-236, astarabine® ou aspacytarabine), leurs procédés de préparation et leurs utilisations pour le traitement de maladies néoplasiques.